Moderna (MRNA) Return on Invested Capital (2020 - 2026)

Moderna has reported Return on Invested Capital for 7 years, with the latest figure at 0.17% in Q2 2026.

• Return on Invested Capital for Q2 2026 came in at 0.17%, down 15.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 0.17% (down 15.0% YoY), and the FY2025 annual result was 0.59%, down 46.0% from the prior year.
• Return on Invested Capital slipped to 0.17% in Q2 2026, from 0.16% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.07% in Q1 2022 and troughed at 0.17% in Q2 2026.
• A 5-year average of 0.03% and a median of 0.02% in 2024 frame the typical range for Return on Invested Capital.
• The widest annual swing landed in 2022, when Return on Invested Capital gained 5 bps; it then fell 15 bps in 2026.
• A 5-year view of Return on Invested Capital shows it stood at 0.02% in 2022, then plunged by 163 bps to 0.01% in 2023, then fell by 29 bps to 0.02% in 2024, then slumped by 635 bps to 0.13% in 2025, then fell by 30 bps to 0.17% in 2026.
• Per Business Quant data, the three most recent Return on Invested Capital figures were 0.17% in Q2 2026, 0.16% in Q1 2026, and 0.13% in Q4 2025.